Senators call for crackdown on pharmaceutical industry ‘revolving door’

Seven Democratic U.S. senators on Thursday introduced legislation designed to slow the “revolving door” between federal agencies such as the Drug Enforcement Administration and the pharmaceutical companies they regulate.

“The pharmaceutical industry has a deep-rooted and strong influence in Washington, and a revolving door between drug companies and government cannot undermine the safety of our communities,” said Sen. Tammy Baldwin (D-Wis.), who sponsored the bill.

The legislation would impose a two-year “cooling off” period on former officials from the DEA and the Food and Drug Administration, barring them from assisting pharmaceutical companies with lobbying efforts.

The bill also expands the definition of “lobbying contact” to include taking part in activities such as strategy sessions. And it limits the issues pharmaceutical industry officials can handle if they join the federal government.

It is not unusual for corporations to hire federal employees directly from the government, nor for industry officials to join the government in high-ranking positions. Industry representatives say the pharmaceutical industry is highly specialized, and they rely upon the expertise of former government officials to help them comply with complex drug laws.

There are regulations designed to prevent potential conflicts of interest.

The current restrictions include a lifetime ban on participating “personally and substantially” on a “particular matter” that the official had handled while working for the federal government.


Government ethics experts say some of those laws are easily skirted.

“The bill could go further, but this is a nice step toward slowing the revolving door that is responsible for steering public policy in favor of the drug companies and distributors rather than in the favor of the public,” said Scott Amey, general counsel for the Project on Government Oversight, a Washington watchdog group.

The proposed legislation follows a joint Washington Post/“60 Minutes” investigation into the opioid industry and its influence in Washington. Companies that manufacture or distribute highly addictive pain pills have hired dozens of high-ranking officials from the DEA during the past decade, many of them from a division that regulates some of the same companies.

A decade ago, DEA investigators began to crack down on large drug companies they suspected of failing to report unusually large orders of painkillers, many of which were winding up in the hands of street dealers and users. Since then, drug companies and the law firms that represent them have hired at least 46 DEA officials — 32 of them directly from the agency’s division that regulates the industry.

One of those DEA officials left the agency and formed a law practice to represent opioid companies. He later helped to write a law that undercut the agency’s enforcement efforts against large companies accused of violating federal drug laws, according to government documents and a legal analysis of the law by the DEA’s chief administrative judge.

Rep. Tom Marino (R-Pa.) introduced the legislation in the House and collected nearly $100,000 from political action committees representing drug companies. In the Senate, the law’s primary sponsor was Sen. Orrin G. Hatch (R-Utah), who negotiated a final version with DEA and Justice Department officials.

In the wake of the Oct. 15 Post/“60 Minutes” investigation, Marino withdrew his nomination to be the nation’s drug czar under the Trump administration.

Several co-sponsors of the Marino bill have since come under fire from their constituents and political opponents for backing the measure at the height of the nation’s worst drug crisis. The prescription drug epidemic has claimed nearly 200,000 lives, more than three times the number of U.S. military deaths in the Vietnam War.

Baldwin said her proposed legislation would serve as a check on the power the pharmaceutical industry wields on Capitol Hill. She cited an investigation by the Associated Press and the Center for Public Integrity that found that the makers of prescription painkillers spent $880 million on campaign contributions and lobbying efforts between 2006 and 2015.

The bill is co-sponsored by Sens. Dianne Feinstein (Calif.), Kamala D. Harris (Calif.), Edward J. Markey (Mass.), Maggie Hassan (N.H.), Jeanne Shaheen (N.H.) and Tom Udall (N.M.) Baldwin said she plans to seek out Republican co-sponsors.

“Patients, families and the public need to have trust that the DEA and FDA are working for them, not powerful Washington interests,” Baldwin said.


Source: Washington Post

PRIVACY

提示条款
iconfont平台提醒您:在使用iconfont平台各项服务前,请您务必仔细阅读并透彻理解本声明。如对本声明内容有任何疑问,您可通过网站下方公布的联系方式联系iconfont进行咨询。如果您不同意本声明或其中任何内容,您应立即停止使用iconfont平台服务。如果您使用iconfont平台服务的,您的使用行为将被视为对本声明全部内容的认可。
定义
iconfont平台:是一个矢量技术交流学习分享的平台,同时为广大用户提供矢量图标存储、字体图标转换等功能的平台(域名为iconfont.cn)。
iconfont:是iconfont平台运营方“淘宝(中国)软件有限公司”的简称。
权利归属
除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。 iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。
iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展... 除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。 iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。
iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展... 除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。 iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。
iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展...